, Volume 52, Issue 6, pp 849–860

Pharmacological Options for the Management of Dyskinesias

Disease Management


Dyskinesias are abnormal involuntary movements characterised by an excessive amount of movement. Typically, these movements are choreiform in nature. They may be caused by systemic, metabolic, endocrinologic, structural, vascular, infectious or inherited degenerative conditions, or be toxin- or drug-induced. With many non-drug-induced dyskinesias, treatment of the underlying condition may be sufficient to eliminate the movements, although temporary treatment may be required to control the movements if they are severe. Drug-induced dyskinesias often resolve when the offending drug is discontinued. A notable exception is tardive dyskinesia, which is caused by exposure to dopamine receptor blocking drugs, the majority of which are antipsychotic agents. Tardive dyskinesias will persist, or may even develop after the causative agent has been stopped and may not spontaneously remit. Another commonly encountered form of drug-induced dyskinesia is seen in patients with Parkinson’s disease who are receiving 1evo-dopa.

Medications which deplete dopamine are most successful in treating choreiform dyskinesias, although anticholinergics, GABAergics, serotonergics, and calcium channel blocking agents have been reportedly beneficial in some cases. Treatment of levodopa-induced dyskinesias requires manipulation of the patient’s antiparkinsonian drug regimen.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Wame RW, Gubbay SS. Choreiform movements induced by anticholinergic therapy. Med J Aust 1979; 1: 465Google Scholar
  2. 2.
    Chadwick D, Reynolds EH, Marsden CD. Anticonvulsantinduced dyskinesias: a comparison with dyskinesias induced by neuroleptics. J Neurol Neurosurg Psychiatry 1976; 39: 1210–8CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Nausieda PA, Koller WG, Weiner WJ, et al. Chorea induced by oral contraceptive. Neurology 1979; 29: 1605–9CrossRefPubMedGoogle Scholar
  4. 4.
    Zorumski CP, Bakris GL. Choreoathetosis associated with lithium: case report and literature review. Am J Psychiatry 1983; 140: 1621–2CrossRefPubMedGoogle Scholar
  5. 5.
    Wedzicha JA, Gibb WR, Lees AJ, et al. Chorea in digoxin toxicity [letter]. J Neurol Neurosurg Psychiatry 1984; 47: 419CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Kushner MJ. Chorea and cimetidine [letter]. Ann Intern Med 1982 Jan; 96(1): 126CrossRefPubMedGoogle Scholar
  7. 7.
    Fahn S. The tardive dyskinesias. In: Matthews WB, Glaser GH, editors. Recent advances in clinical neurology. Edinburgh: Churchill Livingston, 1984: 229–60Google Scholar
  8. 8.
    American Psychiatric Association. Tardive dyskinesia: A task force report of the American Psychiatric Association. Washington, DC: American Psychiatric Association, 1992Google Scholar
  9. 9.
    Fahn S. Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents. In: Fahn S, Calne DB, Shoulson I, editors. Advances in Neurology. Vol 37. Experimental Therapeutics of Movements Disorders. New York: Raven Press, 1983: 267–76Google Scholar
  10. 10.
    Kang UJ, Burke RE, Fahn S. Natural history and treatment of tardive dystonia. Mov Disord 1986; 1: 193–208CrossRefPubMedGoogle Scholar
  11. 11.
    Klawans HL. The pharmacology of tardive dyskinesia. Am J Psychiatry 1973; 130: 82–6CrossRefPubMedGoogle Scholar
  12. 12.
    Burt DR, Creese I, Snyder SH. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 1977; 196: 326–8CrossRefPubMedGoogle Scholar
  13. 13.
    Fibiger HC, Lloyd KG. Neurogiological substrates of tardive dyskinesia: the GABA hypothesis. Trends Neurosci 1984; 7: 462–4CrossRefGoogle Scholar
  14. 14.
    Lohr JB, Kuczenski R, Bracha HS, et al. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiatry 1990; 28: 535–9CrossRefPubMedGoogle Scholar
  15. 15.
    Dinan TG. Calcium-activated potassium conductance: an alternative to the dopamine hypothesis of neuroleptic action? Br J Psychiatry 1987; 151: 455–9CrossRefPubMedGoogle Scholar
  16. 16.
    Klawans HL, Rubovits R. The effect of cholinergic and anticholinergic agents on tardive dyskinesias. J Neurol Neurosurg Psychiatry 1974; 37: 941–7CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Kaufmann CA, Jeste DV, Shelton RC, et al. Noradrenergic and neuroradiological abnormalities in tardive dyskinesia. Biol Psychiatry 1986; 21: 799–812CrossRefPubMedGoogle Scholar
  18. 18.
    Gunne LM, Baranyi S. A primate model for tardive dyskinesia. In: Fann WE, Smith RC, Davis JM, editors. Tardive dyskinesia: research and treatment. New York: S.P. Medical and Scientific Books, 1980: 1–12CrossRefGoogle Scholar
  19. 19.
    Knot V, Egan MF, Hyde TM, et al. Neuroleptics and classic tardive dyskinesia. In: Lang AE, Weiner WJ, editors. Druginduced movement disorders. Mt Kisco: Futura, 1992: 121–66Google Scholar
  20. 20.
    American Psychiatric Association. A task force report of the American Psychiatric Association. Washington, DC: American Psychiatric Association, 1992Google Scholar
  21. 21.
    Shale H, Greene PE, Fahn S. Tardive movement disorders in tic patients treated with dopamine receptor blocking agents [abstract]. Neurology 1989; 39 Suppl. 1: 202Google Scholar
  22. 22.
    Sokoloff P, Giros B, Martres MP, et al. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990; 347: 146–51CrossRefPubMedGoogle Scholar
  23. 23.
    Casey DE. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 1989; 99: S47–53CrossRefPubMedGoogle Scholar
  24. 24.
    Fahn S. Treatment of tardive dyskinesia: use of dopamine-depleting agents. Clin Neuropharmacol 1983; 6: 151–8CrossRefPubMedGoogle Scholar
  25. 25.
    Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol 1995; 18: 197–214CrossRefPubMedGoogle Scholar
  26. 26.
    Login IS, Cronin MJ, MacLeod RM. Tetrabenazine has properties of a dopamine receptor antagonist. Ann Neurol 1982; 12: 257–62CrossRefPubMedGoogle Scholar
  27. 27.
    Klawans HL, Rubovits R. The effect of cholinergic and anticholinergic agents on tardive dyskinesias. J Neurol Neurosurg Psychiatry 1974; 37: 941–7CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Friedhoff AJ. Receptor sensitivity modification (RSM) — A new paradigm for the potential treatment of some hormonal and transmitter disturbances. Comp Psychiatry 1977; 18: 309–17CrossRefGoogle Scholar
  29. 29.
    Lieberman JA, Alvir J, Mukerjee S, et al. Treatment of tardive dyskinesia with bromocriptine. Arch Gen Psychiatry 1989; 46: 908–13CrossRefPubMedGoogle Scholar
  30. 30.
    Goff DC, Renshaw PF, Sarid-Segal O, et al. A placebo-controlled trial of selegiline (L-Deprenyl) in the treatment of tardive dyskinesia. Biol Psychiatry 1993; 33: 700–6CrossRefPubMedGoogle Scholar
  31. 31.
    Lieberman JA, Saltz BL, Johns C, et al. Clozapine effects on tardive dyskinesia. Psychopharmacol Bull 1989; 25: 57–62PubMedGoogle Scholar
  32. 32.
    Trugman JM, Leadbetter R, Zalis ME, et al. Treatment of severe axial tardive dystonia with clozapine: case report and hypothesis. Mov Disord 1994; 9: 441–6CrossRefPubMedGoogle Scholar
  33. 33.
    Glazer WM, Moore DC, Bowers MB, et al. The treatment of tardive dyskinesia with baclofen. Psychopharmacology 1985; 87: 480–3CrossRefPubMedGoogle Scholar
  34. 34.
    Linnoila M, Viukari M, Hietala O. Effect of sodium valproate on tardive dyskinesia. Br J Psychiatry 1976; 129: 114–9CrossRefPubMedGoogle Scholar
  35. 35.
    Bobruff A, Gardos G, Tarsy D, et al. Clonazepam and phenobarbital in tardive dyskinesia. Am J Psychiatry 1981; 138: 189–93CrossRefPubMedGoogle Scholar
  36. 36.
    Thaker GK, Nguyen JA, Straus ME, et al. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry 1990; 147: 445–51CrossRefPubMedGoogle Scholar
  37. 37.
    Lohr JB, Cadet J, Lohr M, et al. Alpha-tocopherol in tardive dyskinesia. Lancet 1987; I: 913–4CrossRefGoogle Scholar
  38. 38.
    Shriqui C, Bradwejn S, Annable L, et al. Vitamin E in the treatment of tardive dyskinesia: a double-blind, placebo-controlled study. Am J Psychiatry 1992; 149: 391–3CrossRefPubMedGoogle Scholar
  39. 39.
    Adler L, Peselow E, Rotrosen J, et al. Vitamin E treatment of tardive dyskinesia. Am J Psychiatry 1993; 150: 1405–7CrossRefPubMedGoogle Scholar
  40. 40.
    Gluskin LE, Strasberg B, Shah JH. Verapamil-induced hyperprolactinemia and galactorrha. Ann Intern Med 1981; 95: 66–7CrossRefPubMedGoogle Scholar
  41. 41.
    Dubovsky SL. Calcium antagonists: a new class of psychiatric drugs. Psychiatric Ann 1986; 16: 724–8CrossRefGoogle Scholar
  42. 42.
    Mangone CA, Herskovits E. Extrapyramidal and depressive reactions with flunarizine and cinnarizine. J Neurol Neurosurg Psychiatry 1989; 52: 288–9CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Barrow N, Childs A. An anti-tardive dyskinetic effect of verapamil [letter]. Am J Psychiatry 1986; 143: 1485PubMedGoogle Scholar
  44. 44.
    Ross J, MacKenzie T, Hanson E, et al. Diltiazem in tardive dyskinesia [letter]. Lancet 1987; I: 268CrossRefGoogle Scholar
  45. 45.
    Duncan E, Adler L, Angrist B, et al. Nifedipine in the treatment of tardive dyskinesia. J Clin Psychopharmacol 1990; 10: 414–6CrossRefPubMedGoogle Scholar
  46. 46.
    Stedman TJ, Whiteford HA, Eyles D, et al. Effects of nifedipine on psychosis and tardive dyskinesia in schizophrenic patients. J Clin Psychopharmacol 1991; 11: 43–7CrossRefPubMedGoogle Scholar
  47. 47.
    Suddath RL, Straw GM, Freed WJ, et al. A clinical trial of nifedipine in schizophrenia and tardive dyskinesia. Pharmacol Biochem Behav 1991; 39: 743–5CrossRefPubMedGoogle Scholar
  48. 48.
    Reiter S, Adler L, Angrist B, et al. Effects of verapamil on tardive dyskinesia and psychosis in schizophrenic patients. J Clin Psychiatry 1989; 50: 26–7PubMedGoogle Scholar
  49. 49.
    Adler L, Duncan E, Reiter S, et al. Effects of calcium-channel antagonists on tardive dyskinesia and psychosis. Psychopharmacol Bull 1988; 24: 423–5Google Scholar
  50. 50.
    Loonen A, Verivey H, Roels P, et al. Is diltiazem effective in treating the symptoms of (tardive) dyskinesia in chronic psychiatric inpatients? A negative, double-blind placebo-controlled trial. J Clin Psychopharmacol 1992; 12: 39–42CrossRefPubMedGoogle Scholar
  51. 51.
    Leys D, Vermesch P, Danel T, et al. Diltiazem for tardive dyskinesia. Lancet 1988; I; 250–1CrossRefGoogle Scholar
  52. 52.
    Yasufuku-Takano J, Sakurai M, Kanazawa I, et al. Successful treatment of intractable tardive dyskinesia with botulinum toxin. J Neurol Neurosurg Psychiatry 1995; 58: 511–2CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Kaufman D. Use of botulinum toxin injections for spasmodic torticollis of tardive dystonia. J Neuropsychiatry Clin Neurosci 1994; 6: 50–3CrossRefPubMedGoogle Scholar
  54. 54.
    Stip E, Faughnan M, Desjardin I, et al. Botulinum toxin in a case of severe tardive dyskinesia mixed with dystonia. Br J Psychiatry 1992; 161: 867–8CrossRefPubMedGoogle Scholar
  55. 55.
    Schrodt GR, Wright JH, Simpson R, et al. Treatment of tardive dyskinesia with propranolol. J Clin Psychiatry 1982; 43: 328–31PubMedGoogle Scholar
  56. 56.
    Nishikawa T, Tanaka M, Tsuda A, et al. Clonidine therapy for tardive dyskinesia and related syndromes. Clin Neuropharmacol 1984; 7: 239–45CrossRefPubMedGoogle Scholar
  57. 57.
    Nasrallah HA, Dunner FJ, Smith RE, et al. Variable clinical response to choline in tardive dyskinesia. Psychol Med 1984; 14: 697–700CrossRefPubMedGoogle Scholar
  58. 58.
    Gelenberg AJ, Doller-Wojcik JC, Growdon JH. Choline and lecithin in the treatment of tardive dyskinesia: preliminary results from a pilot study. Am J Psychiatry 1979; 136: 772–6CrossRefPubMedGoogle Scholar
  59. 59.
    Casey DE. Mood alterations during deanol therapy. Psychopharmacology 1979; 62: 187–91CrossRefPubMedGoogle Scholar
  60. 60.
    Moss LE, Neppe VM, Drevets WC. Buspirone in the treatment of tardive dyskinesia. J Clin Psychopharmacol 1993; 13: 204–9CrossRefPubMedGoogle Scholar
  61. 61.
    Prange AJ, Wilson IC, Morris CE. Preliminary experience with tryptophan and lithium in the treatment of tardive dyskinesia. Psychopharmacol Bull 1973; 9: 36–7Google Scholar
  62. 62.
    Nagao T, Ohshimo T, Mitsunobu K, et al. Cerebrospinal fluid monoamine metabolites and cyclic nucleotides in chronic schizophrenic patients with tardive dyskinesia or drug-induced tremor. Biol Psychiatry 1979; 14: 509–23PubMedGoogle Scholar
  63. 63.
    Gerlach J, Thorsen K, Munkvad I. Effect of lithium in neuroleptic induced tardive dyskinesia compared with placebo in a double-blind cross-over trial. Pharmakopsychiatr Neuropsychopharmakol 1975: 8: 51–6CrossRefPubMedGoogle Scholar
  64. 64.
    Bjorndal N, Casey DE, Gerlach J. Enkephalin, morphine, and noloxone in tardive dyskinesia. Psychopharmacology 1980; 69: 133–6CrossRefPubMedGoogle Scholar
  65. 65.
    Villeneuve A, Cazejust T, Cote M. Estrogens in tardive dyskinesias in male psychiatric patients. Neuropsychobiology 1980; 6: 145–51CrossRefPubMedGoogle Scholar
  66. 66.
    Nutt JG. Dyskinesia induced by levodopa and dopamine agonists in patients with Parkinson’s disease. In: Lang AE, Weiner WJ, editors. Drug-induced movement disorders. Mt Kisco: Futura, 1992: 281–314Google Scholar
  67. 67.
    Factor SA, Weiner WJ. Early combination therapy with dopamine agonists and levodopa. Neurology Forum 1995; 6(3): 3–12Google Scholar
  68. 68.
    Koller WC, Silver DE, Lieberman A, editors. An algorithm for the management of Parkinson’s disease. Neurology 1994; 44 Suppl. 10: S6Google Scholar
  69. 69.
    Klawans HL, Topel JL, Bergen D. Deanol in the treatment of levodopa-induced dyskinesias. Neurology 1975; 25: 290–3CrossRefPubMedGoogle Scholar
  70. 70.
    Tarsy D, Leopold N, Sax D. Physostigmine in choreiform movement disorders. Neurology 1974; 24: 28–34CrossRefPubMedGoogle Scholar
  71. 71.
    Price PA, Parkes JD, Marsden CD. Sodium valproate in the treatment of levodopa-induced dyskinesias. J Neurol Neurosurg Psychiatry 1978; 41: 702–6CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Sheehy MP, Schacter M, Parkes JD, et al. GABA-mimetics, Parkinson’s disease and other movement disorders. In: Rose FC, Capildeo R, editors. Research progress in Parkinson’s disease. Tunbridge Wells: Pitman Medical, 1981: 309–17Google Scholar
  73. 73.
    Klawans HL, Weiner WJ. Attempted use of haloperidol in the treatment of L-dopa-induced dyskinesias. J Neurol Neurosurg Psychiatry 1974; 37: 427–30CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Bennet JP, Landow ER, Schuh LA. Suppression of dyskinesias in advanced Parkinson’s disease: II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Neurology 1993; 43: 1551–5CrossRefGoogle Scholar
  75. 75.
    Fahn S. Fluctuations of disability in Parkinson’s disease: pathophysiology. In: Marsden CD, Fahn S, editors. Movement disorders. London: Butterworths, 1981: 123–34CrossRefGoogle Scholar
  76. 76.
    Victor JF, Pollak P, Gervason C-L, et al. Levodopa-induced diphasic dyskinesias improved by subcutaneous apomorphine. Mov Disord 1992; 7: 283–4CrossRefGoogle Scholar
  77. 77.
    Poewe WH, Lees AJ. The pharmacology of foot dystonia in parkinsonism. Clin Neuropharmacol 1987; 1: 47–56CrossRefGoogle Scholar
  78. 78.
    Jankovic J. Management of motor side effects of chronic levodopa therapy. Clin Neuropharmacol 1981; 5 Suppl. 1: S19–28Google Scholar
  79. 79.
    Shoulson I, Odoroff C, Oakes D, et al. A controlled clinical trial of Baclofen as protective therapy in early Huntington’s disease. Ann Neurol 1989; 25: 252–9CrossRefPubMedGoogle Scholar
  80. 80.
    Shoulson I. Huntington’s disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology 1981; 31: 1333–5CrossRefPubMedGoogle Scholar
  81. 81.
    Barr A, Fischer J, Koller W, et al. Serum haloperidol concentration and choreiform movements in Huntington’s disease. Neurology 1988; 38: 84–8CrossRefPubMedGoogle Scholar
  82. 82.
    Grier LN. corticosteroids in the treatment of Sydenham’s chorea. Arch Neurol 1978; 35: 53–4CrossRefGoogle Scholar
  83. 83.
    Taranata A. Acute rheumatic fever. In: Gellis SS, Kagan BM, editors. Current pediatric therapy, vol. 11. Philadelphia: WB Saunders, 1984; 155–6Google Scholar
  84. 84.
    Dhanaraj M, Radhakrishnan AR, Srinivas K, et al. Sodium valproate in Sydenham’s chorea. Neurology 1985; 35: 114–5CrossRefPubMedGoogle Scholar
  85. 85.
    Daoud AS, Zaki J, Shakir R, et al. Effectiveness of sodium valproate in the treamtent of Sydenham’s chorea. Neurology 1990; 40: 1140–1CrossRefPubMedGoogle Scholar
  86. 86.
    Johnson WG, Fahn S. Treatment of vascular hemiballism and hemichorea. Neurology 1977; 27: 634–6CrossRefPubMedGoogle Scholar
  87. 87.
    Klawans HL. Hemiballismus and other naturally occurring movement disorders. In: Klawans HL, Goetz CG, Tanner CM, editors. Textbook of clinical neuropharmacology and therapeutics. New York: Raven Press, 1992. 139–50Google Scholar
  88. 88.
    Swash M, Roberts AH, Zakko H, et al. Treatment of involuntary movement disorders with tetrabenazine. J Neurol Neurosurg Psychiatry 1972; 35: 186–91CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Obeso JA, Marti-Masso JF, Astudillo W, et al. Treatment of hemiballism with reserpine. Ann Neurol 1978; 6: 581CrossRefGoogle Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  1. 1.The Parkinson’s InstituteSunnyvaleUSA

Personalised recommendations